Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model

Journal of the National Cancer Institute

Volumn 98, Issue 11, 2006, Pages 756-764

  Merchan, Jaime R ^a   Tang, Jian ^b   Hu, Guang ^b   Lin, Yanfeng ^b   Mutter, Walter ^b   Tong, Caili ^a   Karumanchi, S Ananth ^b   Russell, Stephen J ^a   Sukhatme, Vikas P ^b  

^a Mayo Clinic   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CYCLINE; PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; PEPTIDE HYDROLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CLONE; CELL CULTURE; DISEASE COURSE; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; ISOGRAFT; LUNG TUMOR; METABOLISM; METASTASIS; MUTATION; PATHOLOGY; SURVIVAL; UPREGULATION;

ANIMALS; ANTIGENS, CD31; BLOTTING, NORTHERN; CELL PROLIFERATION; CLONE CELLS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MUTATION; PEPTIDE HYDROLASES; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TRANSFECTION; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 33745246331     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj208     Document Type: Article

References (48)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
2. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: A multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003(415 Suppl):S46-58.
3. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J 2000;6 Suppl 2: S134-41.
4. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-92.
5. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49:117-37.
6. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
7. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
8. Cufer T, Borstnar S, Vrhovec I. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 2003; 18:106-15.
9. Cufer T, Vrhovec I, Borstnar S. Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival. Int J Biol Markers 2002; 17:33-41.
10. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-8.
11. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001;152:777-84.
12. Bacharach E, Itin A, Keshet E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A 1992;89:10686-90.
13. Chappuis PO, Dieterich B, Sciretta V, Lohse C, Bonnefoi H, Remadi S, et al. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 2001;19:2731-8.
14. Ferrier CM, Suciu S, van Geloof WL, Straatman H, Eggermont AM, Koops HS, et al. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 2000;83:1351-9.
15. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 1997;94:10868-72.
16. Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 2003;95:388-99.
17. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6.
18. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alpha V beta3 integrin. Cancer cell 2003;3:589-601.
19. Soff GA, Wang H, Cundiff DL, Jiang K, Martone B, Rademaker AW, et al. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: A phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res 2005;11:6218-25.
20. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000;2:331-4.
21. Cohen RL, Xi XP, Crowley CW, Lucas BK, Levinson AD, Shuman MA. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 1991;78:479-87.
22. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 1997;57:3594-9.
23. Higuchi R, Krummel B, Saiki RK. A general method of in vitro preparation and specific mutagenesis of DNA fragments: Study of protein and DNA interactions. Nucleic Acids Res 1988;16:7351-67.
24. Quax PH, Grimbergen JM, Lansink M, Bakker AH, Blatter MC, Belin D, et al. Binding of human urokinase-type plasminogen activator to its receptor: Residues involved in species specificity and binding. Arterioscler Thromb Vase Biol 1998; 18:693-701.
25. Beckley JR, Pauh BU, Elble RC. Re-expression of detachment-inducible chloride channel mCLCA5 suppresses growth of metastatic breast cancer cells. J Biol Chem 2004;279:41634-41.
26. Sloan EK, Stanley KL, Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 2004;23:7893-7.
27. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH, Jankun J. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 2001;8:463-70.
28. Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN, et al. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin Cancer Res 2001;7:2519-26.
29. Choi YK, Yoon BI, Kook YH, Won YS, Kim JH, Lee CH, et al. Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice. Jpn J Cancer Res 2002;93:151-6.
30. Frandsen TL, Holst-Hansen C, Nielsen BS, Christensen IJ, Nyengaard JR, Carmeliet P, et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 2001;61:532-7.
31. McCawley LJ, Crawford HC, King LE, Jr., Mudgett J, Matrisian LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004;64:6965-72.
32. Hayashi S, Yokoyama I, Namii Y, Emi N, Uchida K, Takagi H. Inhibitory effect on the establishment of hepatic metastasis by transduction of the tissue plasminogen activator gene to murine colon cancer. Cancer Gene Ther 1999;6:380-4.
33. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
34. Zacharski LR, Ornstein DL, Gabazza EC, D'Alessandro-Gabazza CN, Brugarolas A, Schneider J. Treatment of malignancy by activation of the plasminogen system. Semin Thromb Hemost 2002;28:5-18.
35. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434-9.
36. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004;22:4683-90.
37. Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 1996;155:858-62.
38. Borstnar S, Vrhovee I, Cufer T. Prognostic value of plasminogen activator inhibitors in breast cancer. Int J Biol Markers 2002; 17:96-103.
39. de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 1999;79:1190-8.
40. Grondahl-Hansen J, Christensen IJ, Briand P, Pappot II, Mouridsen HT, Blichert-Toft M, et al. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 1997;3:233-9.
41. Hansen S, Overgaard J, Rose C, Knoop A, Laenkholm AV, Andersen J, et al. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer 2003;88:102-8.
42. Pavey SJ, Marsh NA, Ray MJ, Butler D, Dare AJ, Hawson GA. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. Boll Soc Ital Biol Sper 1996;72:331-40.
43. Sier CF, Vloedgraven HJ, Ganesh S, Griffioen G, Quax PH, Verheijen JH, et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994;107:1449-56.
44. Milner JM, Elliott SF, Cawston TE. Activation of procollagenases is a key control point in cartilage collagen degradation: Interaction of serine and metalloproteinase pathways. Arthritis Rheum 2001;44:2084-96.
45. Legrand C, Polette M, Tournier JM, de Bentzmann S, Huct E, Monteau M, et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration, Exp Cell Res 2001;264:326-36.
46. Davis GE, Pintar Allen KA, Salazar R, Maxwell SA. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 2001; 114(Pt 5):917-30.
47. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990;32:319-27.
48. Liu G, Shuman MA, Cohen RL. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995;60:501-6.